Alpha-galactosidase

α-Galactosidase ( EC 3.2.1.22, α-GAL, α-GAL A; systematic name α-D-galactoside galactohydrolase) is a glycoside hydrolase enzyme that catalyses the following reaction:[5]

Hydrolysis of terminal, non-reducing α-D-galactose residues in α-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids
This article is about the enzyme. For the carbohydrate commonly called "alpha gal", see Galactose-alpha-1,3-galactose.
α-galactosidase
α-Galactosidase tetramer, Mortierella vinacea
Identifiers
EC no.3.2.1.22
CAS no.9025-35-8
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Search
PMCarticles
PubMedarticles
NCBIproteins
GLA
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesGLA, GALA, galactosidase alpha
External IDsOMIM: 300644 MGI: 1347344 HomoloGene: 90852 GeneCards: GLA
Orthologs
SpeciesHumanMouse
Entrez

2717

11605

Ensembl

ENSG00000102393

ENSMUSG00000031266

UniProt

P06280

P51569

RefSeq (mRNA)

NM_000169

NM_013463

RefSeq (protein)

NP_000160

NP_038491

Location (UCSC)Chr X: 101.39 – 101.41 MbChr X: 133.49 – 133.5 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

It catalyzes many catabolic processes, including cleavage of glycoproteins, glycolipids, and polysaccharides.

The enzyme is encoded by the GLA gene.[6] Two recombinant forms of human α-galactosidase are called agalsidase α (INN) and agalsidase β (INN). A mold-derived form is the primary ingredient in gas relief supplements.

Function

This enzyme is a homodimeric glycoprotein that hydrolyses the terminal α-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose.

Reaction mechanism
A double displacement reaction mechanism of α-GAL's catalytic action.The ligand (black) when bound in the active site of the enzyme (blue). The two key amino acid residues in the active site are Asp-170 and Asp-231. First, Asp-170 performs a nucleophilic attack on the glycosidic bond to release the terminal α-galactose molecule from the ligand. Then, Asp-231 serves as an acid to remove a proton from water, making it more nucleophilic to attack the galactose-Asp complex and release α-galactose from the active site.[7][8][9]

Disease relevance

Signs and Symptoms

Defects in human α-GAL result in Fabry disease, a rare lysosomal storage disorder and sphingolipidosis that results from a failure to catabolize α-D-galactosyl glycolipid moieties.[10] Characteristic features include episodes of pain in hands and feet (acroparesthesia), dark red spots on skin (angiokeratoma), decreased sweating (hypohidrosis), decreased vision (corneal opacity), gastrointestinal problems, hearing loss, tinnitus, etc.. Complications for this disease can be life-threatening and may include progressive kidney damage, heart attack, and stroke. This disease may have late onset and only affect the heart or kidneys.[11]

Fabry disease is an X-linked disease, affecting 1 in 40,000 males. However, unlike other X-linked diseases, this condition also creates significant medical problems for females carrying only 1 copy of the defective GLA gene. These women may experience many classic symptoms of the disorder including cardiac and kidney problems. However, a small number of females carrying only one copy of the mutated GLA gene never shows any symptoms of Fabry disease.

Cause

Mutations to the GLA gene encoding α-GAL may result in complete loss of function of the enzyme. α-GAL is a lysosomal protein responsible for breaking down globotriaosylceramide, a fatty substance stored various types of cardiac and renal cells.[12] When globotriaosylceramide is not properly catabolized, it is accumulated in cells lining blood vessels in the skin, cells in the kidney, heart and nervous system. As a result, signs and symptoms of Fabry disease begin to manifest.[11]

Globotriaosylceramide structure

Treatment

There are three treatment options for Fabry disease: recombinant enzyme replacement therapy, pharmacological chaperone therapy, and organ specific treatment.

Recombinant enzyme replacement therapy (RERT)

RERT was approved as a treatment for Fabry disease in the United States in 2003.[13][14][15]

Two recombinant enzyme replacement therapies are available to functionally compensate for α-galactosidase deficiency. Agalsidase α and β are both recombinant forms of the human α-galactosidase A enzyme and both have the same amino acid sequence as the native enzyme. Agalsidase α and β differ in the structures of their oligosaccharide side chains.[16]

In Fabry disease patients, 88% percent of patients develop IgG antibodies towards the injected recombinant enzyme, as it is foreign to their immune system. One suggested approach to solving this problem involves converting the paralogous enzyme α-NAGAL (NAGA) into one that has with α-GAL activity. Because patients still have a functional NAGA gene, their immune system will not produce NAGA antibodies.[17]

Agalsidase α

The pharmaceutical company Shire manufactures agalsidase alfa (INN) under the trade name Replagal as a treatment for Fabry disease,[18] and was granted marketing approval in the EU in 2001.[19] FDA approval was applied for the United States.[20] However, in 2012, Shire withdrew their application for approval in the United States citing that the agency will require additional clinical trials before approval.[21]

Agalsidase β

The pharmaceutical company Genzyme produces synthetic agalsidase β (INN) under the trade name Fabrazyme for treatment of Fabry disease. In 2009, contamination at Genzyme's Allston, Massachusetts plant caused a worldwide shortage of Fabrazyme, and supplies were rationed to patients at one-third the recommended dose. Some patients have petitioned to break the company's patent on the drug under the "march-in" provisions of the Bayh–Dole Act.[20]

Pharmacological chaperone therapy
Chaperone mode of action[22][23]

Fabry patients who display neurological symptoms cannot receive RERT because recombinant enzymes cannot normally pass the blood-brain barrier. Thus, a more suitable alternative treatment is used: pharmacological chaperone therapy.

It has been shown that more potent competitive inhibitors of an enzyme can act as a more powerful chemical chaperone for the corresponding mutant enzyme that fails to maintain proper folding and conformation, despite its intact active site. These chemical chaperones bind to the active site of the mutant enzyme, which can help promote proper folding and stabilize the mutant enzyme. Thus, this results in functional mutant enzymes that will not be degraded via the ubiquitin-proteasome pathway.

1-Deoxygalactonojirimycin (DGJ) has been shown to be both a potent competitive inhibitor of α-GAL and an effective chaperone to for Fabry disease, increasing intracellular α-GAL's activity by 14-fold.[24][25]

Modifying blood type group B to group O

α-GAL, known as B-zyme in this context, has also demonstrated its ability to convert human blood group B to human blood group O, which can be transfused to patients of all blood types in the ABO blood group categorization. The current B-zyme used comes from Bacteroides fragilis.[23] The idea of maintaining a blood supply at healthcare facilities with all non-O units converted to O units is achieved using enzyme-converted to group O technology, first developed in 1982.[26]

Advantages

A blood bank with ECO blood demonstrates the following advantages:[27]

  • Compatible with and transfusable to patients of all blood groups
  • Reduce the demand for specific ABO blood groups A, B, AB
  • Reduce cost of maintaining a blood bank inventory in hospitals
  • Reduce blood transfusion reactions due to human error and ABO incompatibility
  • Reduce wastage of less needed blood types

Mechanism of Action
Enzyme converted to type O (ECO) technology to convert blood type B to blood type O.

Red blood cell (RBC) surfaces are decorated with the glycoproteins and glycolipids that have the same basic sequence with terminal sugar α1‐2‐linked fucose linked to the penultimate galactose. This galactose molecule is called the H antigen.[28][29][30] Blood type A, B, AB, and O differ only in the sugar (red molecule in the illustration) linked with the penultimate galactose. For blood type B, this linked sugar is an α-1‐3‐linked galactose. Using α-GAL, this terminal galactose molecule can be removed, converting RBC to type O.

Supplements

α-GAL derived from the mold Aspergillus niger is an active ingredient in products marketed to reduce stomach gas production after eating foods known to cause gas. It is optimally active at 55°C, after which its half-life is 120 minutes.[31]

There are scores of supplements containing the enzyme over the counter in the United States and many more world wide. Products with α-galactosidase include:

  • Beano
  • CVS BeanAid
  • Enzymedica's BeanAssist
  • Gasfix
  • Bloateez (in India as Cogentrix)

See also

References
  1. GRCh38: Ensembl release 89: ENSG00000102393 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000031266 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Scriver CR, Sly WS, Childs B, ABeaudet AL, Valle D, Kinzler KW, Vogelstein B (15 December 2000). The Metabolic & Molecular Basis of Inherited Disease (8th ed.). McGraw-Hill. ISBN 978-0-07-913035-8.
  6. Calhoun DH, Bishop DF, Bernstein HS, Quinn M, Hantzopoulos P, Desnick RJ (November 1985). "Fabry disease: isolation of a cDNA clone encoding human α-galactosidase A". Proceedings of the National Academy of Sciences of the United States of America. 82 (21): 7364–8. Bibcode:1985PNAS...82.7364C. doi:10.1073/pnas.82.21.7364. PMC 391345. PMID 2997789.
  7. Koshland DE (1953). "Stereochemistry and the Mechanism of Enzymatic Reactions". Biological Reviews. 28 (4): 416–436. doi:10.1111/j.1469-185x.1953.tb01386.x. S2CID 86709302.
  8. Brumer H, Sims PF, Sinnott ML (April 1999). "Lignocellulose degradation by Phanerochaete chrysosporium: purification and characterization of the main α-galactosidase". The Biochemical Journal. 339 ( Pt 1) (1): 43–53. doi:10.1042/bj3390043. PMC 1220126. PMID 10085226.
  9. Vocadlo DJ, Davies GJ (October 2008). "Mechanistic insights into glycosidase chemistry". Current Opinion in Chemical Biology. 12 (5): 539–55. doi:10.1016/j.cbpa.2008.05.010. PMID 18558099.
  10. "Entrez Gene: GLA galactosidase, alpha".
  11. Reference. "Fabry disease". Genetics Home Reference. Retrieved 2019-03-09.
  12. Ronco C, Bellomo R, Bellasi A (2019). Critical Care Nephrology (Third ed.). Elsevier. pp. 704–711.e2. doi:10.1016/B978-0-323-44942-7.00115-1. ISBN 978-0-323-44942-7. S2CID 86482134.
  13. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (June 2001). "Enzyme replacement therapy in Fabry disease: a randomized controlled trial". JAMA. 285 (21): 2743–9. doi:10.1001/jama.285.21.2743. PMID 11386930.
  14. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (July 2001). "Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease". The New England Journal of Medicine. 345 (1): 9–16. doi:10.1056/nejm200107053450102. PMID 11439963.
  15. Desnick RJ, Schuchman EH (December 2002). "Enzyme replacement and enhancement therapies: lessons from lysosomal disorders". Nature Reviews. Genetics. 3 (12): 954–66. doi:10.1038/nrg963. PMID 12459725. S2CID 11492320.
  16. Fervenza FC, Torra R, Warnock DG (December 2008). "Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease". Biologics: Targets and Therapy. 2 (4): 823–43. doi:10.2147/btt.s3770. PMC 2727881. PMID 19707461.
  17. Tomasic IB, Metcalf MC, Guce AI, Clark NE, Garman SC (July 2010). "Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases". The Journal of Biological Chemistry. 285 (28): 21560–6. doi:10.1074/jbc.M110.118588. PMC 2898384. PMID 20444686.
  18. Keating GM (October 2012). "Agalsidase alfa: a review of its use in the management of Fabry disease". BioDrugs. 26 (5): 335–54. doi:10.2165/11209690-000000000-00000. PMID 22946754.
  19. "Shire Submits Biologics License Application (BLA) for REPLAGAL with the U.S. Food and Drug Administration (FDA)". FierceBiotech. 22 December 2009.
  20. "With A Life-Saving Medicine In Short Supply, Patients Want Patent Broken". NPR.org. 2010-08-04. Archived from the original on 14 September 2010. Retrieved 2010-09-02.
  21. Grogan K (2012-03-15). "Shire withdraws Replagal in USA as FDA wants more trials". PharmaTimes. Archived from the original on 2014-08-19.
  22. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ (July 2001). "Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy". The New England Journal of Medicine. 345 (1): 25–32. doi:10.1056/nejm200107053450104. PMID 11439944.
  23. Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, et al. (April 2007). "Bacterial glycosidases for the production of universal red blood cells". Nature Biotechnology. 25 (4): 454–64. doi:10.1038/nbt1298. PMID 17401360. S2CID 29804004.
  24. Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, Martin OR, Fan JQ (July 2000). "In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives". European Journal of Biochemistry. 267 (13): 4179–86. doi:10.1046/j.1432-1327.2000.01457.x. PMID 10866822.
  25. Fan JQ, Ishii S, Asano N, Suzuki Y (January 1999). "Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor". Nature Medicine. 5 (1): 112–5. doi:10.1038/4801. PMID 9883849. S2CID 13193351.
  26. Goldstein J, Siviglia G, Hurst R, Lenny L, Reich L (January 1982). "Group B erythrocytes enzymatically converted to group O survive normally in A, B, and O individuals". Science. 215 (4529): 168–70. Bibcode:1982Sci...215..168G. doi:10.1126/science.6274021. PMID 6274021.
  27. Olsson ML, Clausen H (January 2008). "Modifying the red cell surface: towards an ABO-universal blood supply". British Journal of Haematology. 140 (1): 3–12. doi:10.1111/j.1365-2141.2007.06839.x. PMID 17970801. S2CID 10668327.
  28. Watkins WM (1980). "Biochemistry and Genetics of the ABO, Lewis, and P blood group systems". Advances in Human Genetics. Springer US. 10: 1–136, 379–85. doi:10.1007/978-1-4615-8288-5_1. ISBN 9781461582908. PMID 6156588.
  29. Oriol R, Le Pendu J, Mollicone R (1986). "Genetics of ABO, H, Lewis, X and related antigens". Vox Sanguinis. 51 (3): 161–71. doi:10.1111/j.1423-0410.1986.tb01946.x. PMID 2433836.
  30. Clausen H, Hakomori S (1989). "ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution". Vox Sanguinis. 56 (1): 1–20. doi:10.1159/000460912. PMID 2464874.
  31. Patil AG, K PK, Mulimani VH, Veeranagouda Y, Lee K (November 2010). "α-Galactosidase from Bacillus megaterium VHM1 and its application in removal of flatulence-causing factors from soymilk". Journal of Microbiology and Biotechnology. 20 (11): 1546–54. doi:10.4014/jmb.0912.12012. PMID 21124061. S2CID 24801055.

Further reading
  • alpha-Galactosidase at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Human GLA genome location and GLA gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.